Question 1

What is DaVita's P/B ratio?

Accepted Answer

DaVita (DVA) P/B ratio is 99.5× as of May 9, 2025. The ratio is calculated by dividing market capitalisation by book value of equity, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/B ratio calculated?

Accepted Answer

P/B = Market Capitalisation ÷ Book Value of Equity (most recent quarterly shareholders' equity), or equivalently Share Price ÷ Book Value Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/B ratio?

Accepted Answer

The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.

Question 4

What is a good P/B ratio for DaVita?

Accepted Answer

A "good" P/B depends on the business model. Banks, insurers, and other capital-heavy financials typically trade near 1×; asset-light technology and consumer-brand companies can sustainably trade at 5×+ because much of their value is intangible. P/B is most informative when paired with return on equity (ROE). For DaVita specifically, the relevant sector benchmark is the current sector median of 3.2×.

Question 5

Is DaVita's P/B ratio high or low?

Accepted Answer

DaVita's P/B ratio of 99.5× is above its own 5-year average of 19.1× and above the sector median of 3.2×. That places the current reading at the 96th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is DaVita's historical P/B ratio range?

Accepted Answer

In the available daily series, DaVita (DVA) P/B ratio has ranged from a low of 2.3× in 2019 to a high of 122.6× in 2025. The 5-year average is 19.1× and the 5-year median is 12.5×.

Question 7

What was DaVita's P/B ratio in 2024?

Accepted Answer

DaVita (DVA) P/B ratio at the end of 2024 was 100.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month book value figure available at that date.

Question 8

Why does DaVita's P/B ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (book value). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$9.78B	-$651M	—	—	Dec 31, 2025
2024	$12.2B	$121M	100.8×	+91.8×	Dec 31, 2024
2023	$9.47B	$1.06B	9.0×	-0.5×	Dec 31, 2023
2022	$6.73B	$712M	9.4×	-5.7×	Dec 31, 2022
2021	$11.5B	$756M	15.2×	+5.7×	Dec 31, 2021
2020	$13.1B	$1.38B	9.5×	+4.9×	Dec 31, 2020
2019	$9.71B	$2.13B	4.6×	+2.2×	Dec 31, 2019
2018	$8.54B	$3.7B	2.3×	-0.5×	Dec 31, 2018
2017	$13.2B	$4.69B	2.8×	+0.1×	Dec 31, 2017
2016	$12.5B	$4.65B	2.7×	-0.3×	Dec 31, 2016
2015	$14.6B	$4.87B	3.0×	-0.1×	Dec 31, 2015
2014	$16.1B	$5.17B	3.1×	+0.1×	Dec 31, 2014
2013	$13.3B	$4.43B	3.0×	+0.0×	Dec 31, 2013
2012	$11.2B	$3.76B	3.0×	-0.3×	Dec 31, 2012
2011	$7.09B	$2.14B	3.3×	-0.1×	Dec 31, 2011
2010	$6.69B	$1.98B	3.4×	+0.6×	Dec 31, 2010
2009	$6.03B	$2.14B	2.8×	+0.2×	Dec 31, 2009
2008	$5.15B	$1.95B	2.6×	-0.8×	Dec 31, 2008
2007	$6.02B	$1.73B	3.5×	-1.3×	Dec 31, 2007
2006	$5.93B	$1.25B	4.8×	-1.3×	Dec 31, 2006
2005	$5.16B	$851M	6.1×	-1.3×	Dec 31, 2005
2004	$3.87B	$523M	7.4×	-0.8×	Dec 31, 2004
2003	$2.51B	$307M	8.2×	-12.9×	Dec 31, 2003
2002	$1.48B	$70.3M	21.1×	—	Dec 31, 2002


Charles River (CRL)	2.6×
Danaher (DHR)	2.6×
Spruce Biosciences (SPRB)	2.6×
Regeneron Pharmaceuticals (REGN)	2.6×
Henry Schein (HSIC)	2.5×
Labcorp Holdings (LH)	2.5×
Solventum (SOLV)	2.3×
Medtronic (MDT)	2.2×
Elevance Health (ELV)	1.9×
Becton, Dickinson and (BDX)	1.8×
Pfizer (PFE)	1.8×
Cigna (CI)	1.7×
Waters Corporation (WAT)	1.6×
Cooper Companies (COO)	1.5×
Universal Health Services (UHS)	1.5×
Biogen (BIIB)	1.4×
Baxter International (BAX)	1.4×
Zimmer Biomet Holdings (ZBH)	1.4×
Revvity (RVTY)	1.4×
CVS Health (CVS)	1.2×
Humana (HUM)	1.1×
Viatris (VTRS)	1.1×
Ovid Therapeutics (OVID)	0.8×
Centene (CNC)	0.8×
Teladoc Health (TDOC)	0.7×

P/B Ratio for DaVita (DVA) 2002-2026

P/B Ratio daily chart for DaVita (DVA)

Historical P/B Ratio for DaVita (DVA) from 2002 to 2025

About P/B Ratio at DaVita (DVA)

DaVita P/B Ratio by Year

DaVita P/B Ratio 2024: 100.8×

DaVita P/B Ratio 2023: 9.0×

DaVita P/B Ratio 2022: 9.4×

DaVita P/B Ratio 2021: 15.2×

DaVita P/B Ratio 2020: 9.5×

Sector peers by P/B Ratio — chart

Sector peers by P/B Ratio — table

Frequently asked questions

DaVita (DVA) Key Financials